OCV

Local media reported Monday that Mumbai-based TechInvention has struck an import deal with EuBiologics to market the South Korean company’s oral cholera vaccine (OCV) in India.

Business Standard quoted TechInvention CEO Syed Ahmed as saying the move fills a market gap resulting from Sanofi’s OCV production pause at its Shantha subsidiary. TechInvention is targeting a price range for Euvichol-Plus of $8-$10 per single dose in India’s private market, according to the article. The company…

India’s Hilleman Laboratories last week announced plans to develop an “effective and affordable" Group B Streptococcus vaccine, paying “close attention” to strains prevalent in India and Southeast Asia, according to a company press release. If successful, the company expects to partner with a vaccine manufacturer for production, a model it followed last year when licensing its oral cholera vaccine candidate to Hyderabad-based Bharat Biotech International Limited.

The press release said…

Seoul-based International Vaccine Institute (IVI) announced last week that the Gates Foundation is giving the nonprofit $1.4 million to develop international standards and reference reagents for oral cholera vaccine manufacturers—upping the foundation’s investment in IVI’s cholera program to $24.4 million to date.

In other news, IVI also announced this week that it has signed a five-year, $5.24 million partnership with the Swedish International Development Cooperation Agency to support…

Mentions:

The Seoul-based International Vaccine Institute (IVI) announced this week that the Gates Foundation is giving it $4.5 million to explore modifications and optimize a single manufacturing process for oral cholera vaccine (OCV) produced by neighboring South Korean manufacturer EuBiologics—with the goal of increasing production capacity and lowering costs.

According to the IVI press release, to date, the Gates Foundation has invested $23 million in the institute’s program to develop a low…

India’s Hilleman Laboratories announced today that it will work with Bharat Biotech International Limited (BBIL) to further develop, manufacture and commercialize its oral cholera vaccine (OCV) candidate.

Hyderabad-based BBIL will scale Hillchol’s manufacturing process to commercial stage and establish product specifications required for WHO pre-qualification, a Hilleman press release said.

Gavi issued a press release last week detailing decisions from its November 2018 board meeting.

Leading the announcements, Gavi said it had provisionally approved support for six new programs as part of its latest Vaccine Investment Strategy. These were a hepatitis B birth dose, diphtheria, pertussis and tetanus-containing boosters, an oral cholera vaccine (OCV), a post-exposure rabies vaccine, a multivalent meningococcal conjugate vaccine, and a respiratory syncytial virus vaccine.…

Results from a follow-up study of cholera cases in Haiti published in the September issue of The Lancet Global Health found that the standard two-dose oral cholera vaccine (OCV) regimen protected for up to four years, with an average cumulative effectiveness rate of 76 percent. The short-term protection provided by a single dose diminished completely within two years, however.

The study is the first to examine long-term protection outside of the historically cholera-endemic areas of…

Gavi issued a press release last week highlighting investment decisions from June’s twice-yearly board meeting.

On polio, the board approved $200 million of core funding to support inactivated polio vaccine (IPV) in 2019 and 2020. Support previously relied on money from the Global Polio Eradication Initiative that is now dwindling. Gavi will consider support to IPV after 2020 at its next board meeting in November 2018 as part of its next five-year Vaccine Investment Strategy (VIS).…

WHO announced in its Global Immunization News last week that it has updated its summary tables of routine immunization recommendations.

BCG, polio, hepatitis B, diphtheria, typhoid and cholera all received updates based on new WHO vaccine position papers or Strategic Advisory Group of Experts (SAGE) on Immunization meeting recommendations.

WHO also updated its references to position papers on measles and HPV.

Two-year follow-up results from a Bangladesh trial published last week in The Lancet Infectious Diseases found that a single dose of oral cholera vaccine provided 52 percent protective efficacy against all cholera episodes and 71 percent protective efficacy against severe cholera in children aged 5-14 and 59 percent protective efficacy against all cholera episodes and also against severe cholera in participants aged over 14.

Similar to previous studies, the vaccine did not show…

Mentions: